Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer demographics, screening and survival outcome at a regional Australian cancer centre: a retrospective study

Date

09 Oct 2016

Session

Poster display

Presenters

Hiren Mandaliya

Citation

Annals of Oncology (2016) 27 (6): 474-482. 10.1093/annonc/mdw387

Authors

H.A. Mandaliya1, C. Oldmeadow2, T. Evans3, P. Troke4, M. George5

Author affiliations

  • 1 Medical Oncology, NORTH WEST CANCER CENTRE, 2340 - Tamworth/AU
  • 2 Clinical Research Design, Information Technology And Statistical Support (creditss), Hunter Medical Research Institute, Newcastle/AU
  • 3 School Of Medicine And Public Health, Faculty Of Health, University of Newcastle, NEWCASTLE/AU
  • 4 Cancer Information, Hunter New England Clinical Cancer Registry, Newcastle/AU
  • 5 Medical Oncology, NORTH WEST CANCER CENTRE, Tamworth/AU
More

Resources

Background

Breast cancer is the third most commonly diagnosed cancer in Australia and the fourth most common cause of death from cancer. This study aimed to describe patient demographics and estimate survival for patients treated at a regional Australian cancer centre.

Methods

A retrospective cohort study was conducted of breast cancer patients who had been treated at North West Cancer Centre from the period of 2008 to 2015. Demographic variables were summarised and estimates of Kaplan-Meier survival for the cohort and breast cancer subtypes were generated. Cox models were used to investigate time to breast cancer-related death for cancer stage, grade, age and distance from the treatment centre. Hazards of death associated with time from diagnosis until treatment and surgery were also assessed.

Results

The cohort comprised of 285 patients that were treated at North West Cancer Centre. Mean and median age was 60 years (range 35-95); three were males. One hundred and twenty-six (44%) patients had screen-detected breast cancer. One hundred and fifty-two (53%) patients had breast conservative surgeries and 117 (41%) underwent mastectomies. Intrinsic histology subtypes Luminal A, Luminal B HER2 positive, Luminal B HER2 negative, HER2 over-expression and triple negative (basal-like) were 75 (29%), 37 (14%), 98 (37%), 12 (4.6%) and 41 (16%) respectively. One hundred and fifty-six (55%) patients received adjuvant chemotherapy, 189 (66%) patients has been on adjuvant endocrine therapy and 149 (52%) patients had adjuvant radiotherapy. Five-year observed survival was 86.9% (95% CI 80.7 - 91.3). Adjusted analyses indicated that increasing stage and age were significantly associated with greater hazard of death (P 

Conclusions

Survival outcome of breast cancer at our regional centre is relatively comparable to Australia wide breast cancer survival. Increasing age and breast cancer stage were associated with a greater hazard of death in adjusted analyses.

Clinical trial identification

Legal entity responsible for the study

Hunter New England Human Research Ethics Committee

Funding

North West Cancer Centre, Tamworth, NSW 2340 Australia

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings